ストックスクリーナーアプリを入手
6.57
12.75%
-0.88
前日終値:
$7.45
開ける：
$7.19
24時間の取引高:
418.75K
Relative Volume:
1.33
時価総額：
$208.77M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+0.00%
1か月 パフォーマンス:
+0.00%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$6.07
$7.19
1週間の範囲:
$6.07
$26.50
52週間の値動き範囲:
$6.07
$26.50
Turn Therapeutics Inc Stock (TTRX) Company Profile
TTRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TTRX
Turn Therapeutics Inc
|
6.475 | 208.77M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.24 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
472.44 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.01 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
801.14 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
330.59 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Turn Therapeutics Inc (TTRX) 最新ニュース
Will Apogee Therapeutics Inc. stock split attract more investorsStock Surge & Safe Swing Trade Setup Alerts - newser.com
Can trapped investors hope for a rebound in Unicycive Therapeutics Inc.Quarterly Earnings Summary & Intraday High Probability Setup Alerts - newser.com
Turn Therapeutics files prospectus relates to offer, sale of up to 7 mln shares - MarketScreener
Stock skyrockets after Turn goes public - BioWorld MedTech
Dow Dips Over 250 Points; Delta Air Lines Posts Upbeat Earnings - Benzinga
Turn Therapeutics (TTRX) Skyrockets After Nasdaq Debut – Biotech Breakthrough or Hype? - ts2.tech
Strength Seen in Septerna, Inc. (SEPN): Can Its 7.0% Jump Turn into More Strength? - Yahoo Finance
US Stocks Mixed; Nasdaq Falls Over 50 Points - Benzinga
Pre-Market Titans: TTRX, BJDX & UPC Set The Pace - RTTNews
Stock Market Today: S&P 500, Nasdaq Futures Slip As Fed Minutes Signal Tariff-Related Uncertainty—PepsiCo, Delta, Levi Strauss In Focus (UPDATED) - Benzinga
Why Richardson Electronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket - Benzinga
Why Is Turn Therapeutics Stock Soaring Over 370% Premarket Today? - MSN
Turn Therapeutics Shares Skyrocket 134% After Hours Following Nasdaq Debut - Benzinga
After-Hours Surge: Turn Therapeutics Rockets 134% Post-Close On Nasdaq Debut; Biotech Stocks Rally - Nasdaq
Turn Therapeutics Inc.Common Stock (Nasdaq:TTRX) Stock Quote - FinancialContent
Turn Therapeutics to Commence Trading Today on Nasdaq - Yahoo Finance
Turn Therapeutics (Direct Listing) Plans $0.00 IPO for Week of October 13th (TTRX) - Defense World
Sarepta Therapeutics Stock Skyrockets After FDA U-Turn – Gene Therapy Drama Explained! - ts2.tech
Turn Therapeutics Inc. Announces Board and Committee Appointments, Effective September 30, 2025 - MarketScreener
Crystalys Therapeutics Launches with $205M Series A Financing to Transform the Treatment of Gout - PR Newswire
Turn Therapeutics Announces Expected First Day of Trading on NASDAQ Global Market - Business Wire
Can Zevra Therapeutics (ZVRA) Turn Clinical Momentum Into Sustainable Competitive Advantage? - Yahoo Finance
This Sarepta Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday - Benzinga
Strength Seen in Amicus Therapeutics (FOLD): Can Its 6.4% Jump Turn into More Strength? - Yahoo Finance
Turn Therapeutics to Host Open Investor Session in Connection with Expected Public Listing on Nasdaq - Business Wire
Strength Seen in Silicon Motion (SIMO): Can Its 6.4% Jump Turn into More Strength? - Yahoo Finance
Strength Seen in Travere (TVTX): Can Its 26.2% Jump Turn into More Strength? - Yahoo Finance
After dropping IPO plans, Odyssey Therapeutics turns to VC for capital - The Business Journals
impact.com Announces Sustained Growth in Q2 2025 as Consumers Turn to Authentic Connections with Trusted Communities and Brands - Yahoo Finance
TTRX IPO NewsWound and dermatology-focused Turn Therapeutics files for a direct listing on the Nasdaq - renaissancecapital.com
Superbug Survivor and Turn Therapeutics CEO Launches Podcast to Spotlight Hidden Scientific Breakthroughs - Business Wire
Glenmark Pharma will turn cash positive with AbbVie's licensing deal: S&P - The Economic Times
Turn Therapeutics Begins Clinical Trial of First Topical IL-36/IL-31 Inhibitor for Eczema - Business Wire
This Sarepta Therapeutics Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday - Benzinga
Strength Seen in Nektar (NKTR): Can Its 12.1% Jump Turn into More Strength? - Yahoo Finance
When Will Amicus Therapeutics, Inc. (NASDAQ:FOLD) Turn A Profit? - simplywall.st
China is catching up to the U.S. in pharmaceuticals, but it’s not too late to turn that around - Fast Company
Vertical Aerospace Ltd. (NYSE:EVTL) Is About To Turn The Corner - Yahoo Finance
Allogene Therapeutics: Still Looking Shaky, But Looking To Turn The Corner (Rating Upgrade) - Seeking Alpha
With Trials In Motion, Cash To 2027, Can Kyverna's Next Data Drop Turn The Stock Around? - Benzinga
Turn Therapeutics Announces Vaccine Breakthrough: Validates 100% VSV Recovery from Petrolatum Carrier at 24 and 72 Hours - Business Wire
Strength Seen in Recursion Pharmaceuticals (RXRX): Can Its 27.7% Jump Turn into More Strength? - Yahoo Finance
Spevigo so-so, innovator takes another Turn at IL-36 in eczema - BioWorld MedTech
When Will Rakovina Therapeutics Inc. (CVE:RKV) Turn A Profit? - Yahoo Finance
Turn Therapeutics Launches Final Crowdfund Round Ahead of Eczema Trial Enrollment, Engages Clear Street to Explore Public Markets - Business Wire
Turn Biotechnologies Acquires ARMMs Vesicular Technology to Increase Access to Tissue Targets for Its Epigenetic Reprogramming Therapies - PR Newswire
Cell therapy biotech Century Therapeutics axes cancer trial, turns to autoimmune - fiercebiotech.com
Strength Seen in TG Therapeutics (TGTX): Can Its 10.2% Jump Turn into More Strength? - Yahoo Finance
Biotech startup looks to turn founders' experience, $20 million against epilepsy - The Business Journals
Can Contineum's Upcoming Catalysts Turn The Tide In The Coming Months? - RTTNews
TransCode Therapeutics: A Turning Point for RNAZ? - StocksToTrade
Turn Therapeutics Inc (TTRX) 財務データ
Turn Therapeutics Inc (TTRX) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
1.19%
大文字化:
|
ボリューム (24 時間):